ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SLP Simulations Plus Inc

48.21
1.51 (3.23%)
After Hours
Last Updated: 23:31:41
Delayed by 15 minutes
Share Name Share Symbol Market Type
Simulations Plus Inc NASDAQ:SLP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.51 3.23% 48.21 42.90 49.99 48.31 46.79 47.17 89,381 23:31:41

Simulations Plus to Present at the Needham Emerging Technology Conference

11/05/2017 1:30pm

Business Wire


Simulations Plus (NASDAQ:SLP)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Simulations Plus Charts.

Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, announced today that Walt Woltosz, chairman and chief executive officer, will present at the Needham Emerging Technology Conference on Wednesday, May 17, 2017, at 12:50 p.m. EDT. The conference will be held at the Westin Grand Central Hotel in New York City.

For more information on Needham’s Emerging Technology Conference, please visit http://www.needhamco.com/.

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn

Simulations Plus Investor RelationsMs. Renee Bouche, 661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron Donahue, 651-653-1854cameron@haydenir.com

1 Year Simulations Plus Chart

1 Year Simulations Plus Chart

1 Month Simulations Plus Chart

1 Month Simulations Plus Chart

Your Recent History

Delayed Upgrade Clock